Payers Embrace Value-Based Care Models for Cell and Gene Therapies
At the Asembia ASX26 Summit in Las Vegas, Will Shrank, CEO of Aradigm Health, discussed how healthcare payers are increasingly adopting value-based care models for cell and gene therapies. Despite the promise of these advanced treatments, high costs remain a significant barrier for both research and patient administration. Shrank noted that while previous value-based contracts often lacked genuine financial alignment between manufacturers and purchasers, the unique nature of cell and gene therapies is driving change. Unlike traditional drugs, these therapies often aim for cures with binary outcomes, such as whether a hemophilia patient suffers a bleed or a sickle cell patient experiences a crisis. This clarity makes it easier to measure success and align interests. The substantial cost magnitude creates an urgent need for meaningful contracts that tie payment to actual patient outcomes. Consequently, the industry is moving toward more robust agreements that ensure manufacturers and payers share financial risks and rewards based on therapeutic effectiveness, marking a significant shift in how these high-cost treatments are managed and reimbursed within the healthcare system.
Wire timeline
Payers Embrace Value-Based Care Models for Cell and Gene Therapies
At the Asembia ASX26 Summit in Las Vegas, Will Shrank, CEO of Aradigm Health, discussed how healthcare payers are increasingly adopting value-based care models for cell and gene therapies. Despite the promise of these advanced treatments, high costs remain a significant barrier for both research and patient administration. Shrank noted that while previous value-based contracts often lacked genuine financial alignment between manufacturers and purchasers, the unique nature of cell and gene therapies is driving change. Unlike traditional drugs, these therapies often aim for cures with binary outcomes, such as whether a hemophilia patient suffers a bleed or a sickle cell patient experiences a crisis. This clarity makes it easier to measure success and align interests. The substantial cost magnitude creates an urgent need for meaningful contracts that tie payment to actual patient outcomes. Consequently, the industry is moving toward more robust agreements that ensure manufacturers and payers share financial risks and rewards based on therapeutic effectiveness, marking a significant shift in how these high-cost treatments are managed and reimbursed within the healthcare system.
PharmExec articles